In the BioHarmony Drug Report Database

"Preview" Icon

Tobramycin

Bethkis, Kitabis Pak, Tobi, Tobi Podhaler, Tobrex, Tobramycin PARI, Vantobra (tobramycin) is a small molecule pharmaceutical. Tobramycin was first approved as Bethkis on 1982-01-01. It is used to treat bacterial eye infections, bacterial infections, central nervous system infections, infectious bone diseases, and infectious skin diseases amongst others in the USA. It has been approved in Europe to treat cystic fibrosis and respiratory tract infections. Tobrex’s patents are valid until 2030-11-04 (FDA).

 

Trade Name

 

Tobi Podhaler, Tobramycin PARI, Vantobra
 

Common Name

 

tobramycin
 

ChEMBL ID

 

CHEMBL1747
 

Indication

 

bacterial eye infections, bacterial infections, central nervous system infections, cystic fibrosis, infectious bone diseases, infectious skin diseases, intraabdominal infections, pseudomonas infections, respiratory tract infections, staphylococcal infections, urinary tract infections
 

Drug Class

 

Antibiotics (Streptomyces strains)

Image (chem structure or protein)

Tobramycin structure rendering